XML 29 R18.htm IDEA: XBRL DOCUMENT v3.22.1
Related-Party Transactions
 3 Months Ended
Mar. 31, 2022
Related Party Transactions [Abstract]  
Related-Party Transactions

(12)

Related-Party Transactions

In June 2019, the Company expanded its collaboration and entered into an agreement with Ginkgo for the research and development of engineered microbial therapeutic products. As of March 31, 2022, Ginkgo owns 6,340,771 shares of the Company’s outstanding common stock. See Note 10, Ginkgo Collaboration, in the audited financial statements included in the 2021 Annual Report.

Under the agreement the Company made a prepayment to Ginkgo of $30.0 million for its foundry services that will be provided to the Company over an initial term of five years. At March 31, 2022, the Company had remaining balances of $0.9 million and $9.8 million of current and non-current pre-paid research and development costs related to this transaction, respectively. For the three months ended March 31, 2022, the Company used $0.5 million of the pre-paid research and development expenses.